Why the study?
Does double-dose clopidogrel and high-dose aspirin improve 30-day outcomes in individuals undergoing percutaneous coronary intervention for acute coronary syndromes compared with standard doses?
Does double-dose clopidogrel and high-dose aspirin improve 30-day outcomes in individuals undergoing percutaneous coronary intervention for acute coronary syndromes compared with standard doses?
In patients undergoing PCI for ACS, double-dose clopidogrel reduces 30-day ischemic events but increases major bleeding, whereas high-dose aspirin offers no advantage over low-dose aspirin.
Commentary on: SR Mehta, JF Tanguay, JW Eikelboom, et al.; CURRENT-OASIS 7 trial investigators. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.Lancet2010;376:1233–43.
No takes yet. Share an insight, caveat, or question.
Lala et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: